Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.53 |
| ▸ | NMT1 | P30419 | 1/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 3/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL605560 | 0.92 | NMT2 (0.55) | NMT2NMT1LPAR3LPAR1FAAH | |
| SCHEMBL8296140 | 0.82 | PLA2G10 (0.49) | LPAR3LPAR1FAAHMEN1MAPK1 | |
| SCHEMBL608031 | 0.82 | NMT2 (0.56) | NMT2NMT1LPAR3LPAR1FAAH | |
| SCHEMBL3174506 | 0.81 | KMT2A (0.47) | NMT2NMT1LPAR3LPAR1FAAH | |
| SCHEMBL607465 | 0.81 | L3MBTL1 (0.51) | NMT2NMT1LPAR3LPAR1MEN1 | |
| SCHEMBL606724 | 0.80 | EPHX1 (0.52) | — | |
| SCHEMBL606965 | 0.80 | FAAH (0.46) | LPAR3LPAR1FAAHMEN1MAPK1 | |
| SCHEMBL607376 | 0.80 | NMT2 (0.60) | NMT2NMT1LPAR3LPAR1FAAH | |
| SCHEMBL26032021 | 0.80 | FAAH (0.54) | LPAR3LPAR1FAAHMEN1MAPK1 | |
| SCHEMBL3165538 | 0.78 | PSMB5 (0.64) | FAAHMEN1MAPK1KMT2APLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8546608-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8058262-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | NMT2 2957/4885NMT1 3142/4885LPAR3 3911/4885 |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | NMT2 2957/4885NMT1 3142/4885LPAR3 3911/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | NMT2 2957/4885NMT1 3142/4885LPAR3 3911/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | NMT2 2957/4885NMT1 3142/4885LPAR3 3911/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | NMT2 2957/4885NMT1 3142/4885LPAR3 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.